125 results about "Endometrioses" patented technology

The present invention relates to a combination of resveratrol with progestogen, and medicaments and pharmaceutical compositions containing the same, which are useful in the treatment and/or prevention of myoma and/or endometriosis, providing their size reduction and the control of related symptoms. Said association may additionally comprise an estrogen component. A treatment method and a kit are also objects of this invention.

Metastin, compounds that promote the activity of metastin or its receptors and the like are excellent gonadal function improving agents, ovulation inducers or promoters, gonadotropic hormone secretion promoters, gonadotropic hormone secretion inhibitors, sex hormone secretion promoters, sex hormone secretion inhibitors, etc., and can be used as agents for preventing/treating sterility, hormone-sensitive cancers, endometriosis, etc. Metastin and its receptors are useful for screening for these pharmaceuticals.

The invention relates to newly discovered marker polypeptides associated with endometriosis. Compositions, kits, and methods for detecting, characterizing, preventing, and treating endometriosis are provided.

The invention discloses a Chinese medicine composition for treating endometriosis uterine, belonging to the technical field of Chinese medicine, which is characterized in that a plurality of medicinal herbs, such as radix salviae miltiorrhizae, motherwort, Rhizoma Zedoariae, semen coicis, dragon's blood are used as raw materials, and undergo the processes of alcohol extraction and water extraction according to relevant compatibility requirements, so as to produce the intended medicine preparation, and the Chinese medicine composition is optimally manufactured into capsules. The Chinese medicine composition has an advantage of remarkable curative effect for endometriosis uterine.

The invention relates to a pharmaceutical combined preparation of LHRH analogues and anti-oestrogens having tissue-selective oestrogen activity and also to its use for the treatment of gynaecological disorders, especially for the treatment of endometrioses and myomas.

The invention relates to the field of traditional Chinese medicines, in particular to an external traditional Chinese medicine composition for relieving chronic pelvic pain and dysmenorrheal caused by endometriosis. The external traditional Chinese medicine composition is prepared from the following raw herbal materials in part by weight: 6-12 parts of radix aconiti preparata, 6-12 parts of folium artemisiae argyi, 20-40 parts of spatholobus suberctu, 10-20 parts of Cortex Illicii, 10-30 parts of saposhnicovia divaricata, 10-30 parts of cortex acanthopanacis, 10-20 parts of radix angelicae, 10-20 parts of lycopodium clavatum, 10-20 parts of flos carthami, 10-20 parts of notopterygium root, 10-20 parts of radix angelicae pubescentis and 10-20 parts of speranskia tuberculata. The external traditional Chinese medicine composition has the advantages that effects of warming the channel and dispersing cold, promoting blood circulation to remove blood stasis, relieving swelling and pain and the like are achieved, according to clinical application for many years and pharmacological study, chronic pelvic pain and dysmenorrheal caused by endometriosis can be relieved obviously, effects are remarkable, and the external traditional Chinese medicine composition is economical and convenient, is low in side effect, has an obvious curative effect, does not have toxic or side effects, is low in cost, and is convenient to popularize and use.

High affinity relaxin receptors, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided. These proteins, herein termed LGR7 and LGR8, are orphan leucine-repeat-containing, G protein-coupled receptors. These receptors have a wide and a unique tissue expression pattern. The receptors, particularly soluble fragments thereof, are useful as therapeutic agents capable of inhibiting the action of relaxin and lnsL3. The receptors and fragments thereof also find use in the screening and design of relaxin agonists and antagonists. Conditions treatable with relaxin agonists or antagonists include prevention or induction of labor, treatment of endometriosis, treatment of skin conditions such as scleroderma that require collagen or extracellular matrix remodelling. Additionally, relaxin has been implicated in the dilation of blood vessels' smooth muscle cells directly and through release of nitric oxide and atrial natriuretic peptide. Relaxin has also been used in the treatment of severe chronic pain, particularly pain arising from stretching, swelling, or dislocation of tissues.

The invention relates to a preparation method and a quality control method of a new drug, Danazol Vaginal Tablets, for treating endometriosis with clear dysmenorrhea symptom but light physical sign. The drug can be delivered via cavitary mucosa, so as to prevent or relieve the possible adverse reactions due to systemic drug delivery; the effective drug concentration at lesion site is high, so as to be in favor of exert curative action; and the added lactic acid-calcium lactate buffer system results in the drug with pH of 3.5-4.0 that is similar to the physiological pH in vagina, so as to effectively retain physiological environment in vagina, provide existing conditions suitable for vaginal beneficial bacteria, and promote rehabilitation.

Retrosteroidal compounds corresponding to formula I, representing progesterone receptor modulators, and their production, and pharmaceutical preparations containing these compounds. These compounds are useful in the treatment of benign gynecological disorders such as endometriosis and uterine fibroids, as well as for female birth control and for hormone replacement therapy.

The present invention is related to Selective Progesterone Receptor Modulators (SPRM) as described and defined herein, and covers the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of sexual hormone dependent diseases and gynaecological diseases in particular Endometriosis or Uterine Fibroids (UF), as a sole agent or in combination with other active ingredients wherein circulating endogenous estradiol concentration of treated women is maintained to a level in a range of 40 pg/mL to 85 pg/mL.

Disclosed herein are compositions and methods useful for the diagnosis, assessment, and characterization of endometriosis in a subject in need thereof, based upon the expression level of at least onemiRNA that is associated with endometriosis.

The present disclosure provides improved methods of providing endometriosis testing to patients, as well as improved methods of monitoring and adjusting endometriosis treatments.

The invention relates to a preparation method of total alkali of corydalis tuber, and a corydalis tuber preparation and use thereof. The preparation method of the total alkali of corydalis tuber, which is prepared by the invention, comprises: grinding, extracting and post-treatment, wherein the post-treatment comprises extracting ethyl acetate, concentrating, freezing and drying. In the invention, an ethyl acetate extracting method is adopted, so the recovery is easy, the recovery rate is high, the toxicity is low, the environment pollution is avoided, and ethyl acetate is an ideal solvent for industrial production; and the drawbacks of high volatility, low recovery rate, high production cost, and high toxicity to human beings and the environment of the conventional biological alkali extraction solvents which mainly are chloroform are overcome, and the production cost is reduced. The ethyl acetate extraction purity reaches over 80 percent. The invention also provides a corydalis tubertotal alkali preparation and the use of the corydalis tuber total alkali preparation in the preparation of medicines for treating gynecological diseases, in particular the use of the corydalis tuber total alkali preparation in the preparation of medicines for treating dysmenorrheal, abnormal menstruation or endometriosis.

The invention provides a kit for endometriosis diagnosis. The kit comprises 1) an EDTA-K2 anticoagulative tube for collecting peripheral blood, 2) a cryopreservation tube for preloading Trizol, 3) a reagent for extracting total RNA in peripheral blood, 4) a reagent for detecting miRNA-141 and U6 gene expression, and 5) a formula of calculating miRNA-141 scores in blood: miRNA-141 score = miRNA-141Ct value - U6Ct value. The kit has high repeatability and stability and no repeated experiment is required. MiRNA-141 and U6 are utilized to amplify a nucleic acid sequence, the diagnosis kit for determining miRNA score in the blood is constructed, the goal of noninvasive diagnosis of endometriosis can be achieved, the damage to patients caused by laparoscope detection is greatly reduced, and the kit is favorable for early treatment of the endometriosis.

The invention relates to a medicine for treating endometriosis, in particular to a Chinese medicine oral decoction for treating endometriosis, which is prepared by using Chinese herbal medicines as raw materials. The invention adopts the technical scheme that the Chinese medicine oral decoction comprises the following raw medicinal materials in parts by weight: 5-15g of Chinese angelica, 5-15g of salvia miltiorrhiza, 3-12g of rehmanniae praeparatum, 5-15g of crude pollen typhae, 1-5g of dragon's blood, 3-12g of India madder roots and 1-5g of pseudo-ginseng powder. In the invention, all the raw medicinal materials are reasonably mixed to achieve the efficacies of promoting blood circulation and removing blood stasis, stopping pain, removing heat from the blood and stopping bleeding, calming the mind, relaxing bowel, and the like. Through the synergistic effect, the Chinese medicine oral decoction can treat both principal and secondary aspects of endometriosis, and has no side effect. By oral administration, the Chinese medicine oral decoction can regulate inner body, strengthen the body resistance to consolidate the constitution, regulate endocrine disturbance, enhance immune functions of human bodies, balance yin and yang, restore the Zang-Fu functions in dynamic balance, and effectively treat endometriosis. The invention has the advantages of obvious effect, economy, practicability and simple method, and can be operated independently. The invention is mainly applicable to patients with endometriosis accompanied with menorrhagia.

Pyrazolopyrimidone and pyrrolotriazone derivatives, methods of preparation thereof, and pharmaceutical uses thereof are described. Specifically, pyrazolopyrimidone and pyrrolotriazone derivatives represented by the general formula (I) and pharmaceutically acceptable salts thereof are described. The pyrazolopyrimidone and pyrrolotriazone derivatives are useful as gonadotropin releasing hormone (GnRH) antagonists, such as for therapeutic agents for endometriosis. The definitions of the substituents in the general formula (I) are the same as the definitions in the specification.